Preclinical startup Jecure makes bee-line to exit with Genentech buyout
Venture capital firm Versant Ventures launched the company with a $20 million Series A funding round last year.
Jecure Therapeutics
Venture capital firm Versant Ventures launched the company with a $20 million Series A funding round last year.